Immunotherapeutic Advances in Brain Tumors

The interface between immunology and oncology has introduced revolutionary strategies for targeting malignancies, including those within historically complex regions such as the brain. Despite the central nervous system's reputation as an immune-privileged area, recent research validates the potential of immunotherapy in treating both primary and secondary brain tumors. Techniques such as the utilization of dendritic cells primed with tumor-derived materials or RNA and the application of immune checkpoint inhibitors to release brakes on immune responses offer promising pathways to enhance anti-tumor activity.

This Research Topic aims to explore the forefront of immunotherapy applications for brain tumors, seeking to understand mechanisms, enhance efficacy, and broaden the scope of treatment. Specifically, the research will probe the following two "how's":
--How novel immunotherapeutic strategies can overcome the localized immunosuppression typical of aggressive brain cancers
--How novel immunotherapeutic strategies can incite prolonged and potent immune responses against aggressive brain cancers

Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.

Keywords: Brain Tumors, Gliomas, Cytokine gene vaccine therapy, Immunotherapy, Angiogenesis, Check-point inhibitors, Dendritic cell therapy

Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.